Avtor/Urednik		Twelves, Chris; Bartsch, Rupert; Ben-Baruch, Noa Efrat; Borštnar, Simona; Dirix, Luc Yves; Tesarova, Petra; Timcheva, Constanta; Zhukova, Lyudmila; Pivot, Xavier
Naslov		The place of chemotherapy in the evolving treatment landscape for patients with HR-positive/HER2-negative MBC
Tip		članek
Vol. in št.		Letnik 22, št. 3
Leto izdaje		2022
Obseg		str. 223-234
ISSN		1526-8209 - Clinical breast cancer
Jezik		eng
Abstrakt		Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines current HR-positive/HER2-negative MBC clinical guidelines and addresses key questions around the use of chemotherapy in the face of emerging therapeutic options. Specifically, the indications for chemotherapy in patients with HR-positive/HER2-negative MBC and the choice of optimal chemotherapy are discussed.
Proste vsebinske oznake		kemoterapija citotoksičnost hormonsko pozitivni rak metastatski rak dojke chemotherapy cytotoxic HR positive metastatic breast cancer